363 related articles for article (PubMed ID: 23622849)
21. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.
Woldu H; Porta G; Goldstein T; Sakolsky D; Perel J; Emslie G; Mayes T; Clarke G; Ryan ND; Birmaher B; Wagner KD; Asarnow JR; Keller MB; Brent D
J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):490-8. PubMed ID: 21515198
[TBL] [Abstract][Full Text] [Related]
23. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
24. Treatment Outcomes in Anxious Youth with and without Comorbid ADHD in the CAMS.
Halldorsdottir T; Ollendick TH; Ginsburg G; Sherrill J; Kendall PC; Walkup J; Sakolsky DJ; Piacentini J
J Clin Child Adolesc Psychol; 2015; 44(6):985-91. PubMed ID: 25310142
[TBL] [Abstract][Full Text] [Related]
25. Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety.
Strawn JR; Mills JA; Suresh V; Peris TS; Walkup JT; Croarkin PE
J Affect Disord; 2022 Feb; 298(Pt A):292-300. PubMed ID: 34728290
[TBL] [Abstract][Full Text] [Related]
26. Comorbid disorders as moderators of response to family interventions among adolescents with bipolar disorder.
Weintraub MJ; Axelson DA; Kowatch RA; Schneck CD; Miklowitz DJ
J Affect Disord; 2019 Mar; 246():754-762. PubMed ID: 30623821
[TBL] [Abstract][Full Text] [Related]
27. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
28. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).
Piacentini J; Bennett S; Compton SN; Kendall PC; Birmaher B; Albano AM; March J; Sherrill J; Sakolsky D; Ginsburg G; Rynn M; Bergman RL; Gosch E; Waslick B; Iyengar S; McCracken J; Walkup J
J Am Acad Child Adolesc Psychiatry; 2014 Mar; 53(3):297-310. PubMed ID: 24565357
[TBL] [Abstract][Full Text] [Related]
29. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
[TBL] [Abstract][Full Text] [Related]
30. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
[TBL] [Abstract][Full Text] [Related]
31. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis.
Wang Z; Whiteside SPH; Sim L; Farah W; Morrow AS; Alsawas M; Barrionuevo P; Tello M; Asi N; Beuschel B; Daraz L; Almasri J; Zaiem F; Larrea-Mantilla L; Ponce OJ; LeBlanc A; Prokop LJ; Murad MH
JAMA Pediatr; 2017 Nov; 171(11):1049-1056. PubMed ID: 28859190
[TBL] [Abstract][Full Text] [Related]
33. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
McIntyre A; Gendron A; McIntyre A
Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
[TBL] [Abstract][Full Text] [Related]
34. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
Am J Psychiatry; 2019 Apr; 176(4):275-286. PubMed ID: 30764648
[TBL] [Abstract][Full Text] [Related]
35. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Brent DA
Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
[No Abstract] [Full Text] [Related]
36. Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Koenig AM; Butters MA; Begley A; Ogbagaber S; Wahed AS; Reynolds CF
J Clin Psychiatry; 2014 Feb; 75(2):e100-7. PubMed ID: 24602256
[TBL] [Abstract][Full Text] [Related]
37. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
38. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
39. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
40. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
